Literature DB >> 16670082

Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

Angel F Remacha, Josep F Nomdedéu, Guiomar Puget, Camino Estivill, M Pilar Sarda, Carme Canals, Anna Aventin.   

Abstract

The JAK2/V617F mutation has been noted in essential thrombocytemia. We investigated 19 cases with refractory anemia with ringed sideroblasts (RARS), including three RARS with thrombocytosis (RARS-T). Only the RARS-T patients showed this mutation. More cases need to be analyzed to determine the prevalence of the JAK2/V617F mutation in RARS-T.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16670082

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  7 in total

Review 1.  Do we know more about essential thrombocythemia because of JAK2V617F?

Authors:  Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

2.  Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Authors:  Julien Broseus; Lourdes Florensa; Esther Zipperer; Susanne Schnittger; Luca Malcovati; Steven Richebourg; Eric Lippert; Jaroslav Cermak; Jyoti Evans; Morgane Mounier; José Maria Raya; François Bailly; Norbert Gattermann; Torsten Haferlach; Richard Garand; Kaoutar Allou; Carlos Besses; Ulrich Germing; Claudia Haferlach; Erica Travaglino; Elisa Luno; Maria Angeles Pinan; Leonor Arenillas; Maria Rozman; Maria Luz Perez Sirvent; Bernardine Favre; Julien Guy; Esther Alonso; Nuhri Ahwij; Andrés Jerez; Sylvie Hermouet; Marc Maynadié; Mario Cazzola; François Girodon
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

3.  Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.

Authors:  J M Raya; L Arenillas; A Domingo; B Bellosillo; G Gutiérrez; E Luño; M A Piñán; M Barbón; M L Pérez-Sirvent; M J Muruzábal; L Yánez; L García; A Lemes; J T Navarro; A Elosegi; M A Cortés; A Villegas; M A Durán; M Ardanaz; L Florensa
Journal:  Int J Hematol       Date:  2008-09-27       Impact factor: 2.490

Review 4.  A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.

Authors:  K Gnanasambandan; P P Sayeski
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.

Authors:  Shashidhar S Jatiani; Stephen C Cosenza; M V Ramana Reddy; Ji Hee Ha; Stacey J Baker; Ajoy K Samanta; Matthew J Olnes; Loretta Pfannes; Elaine M Sloand; Ralph B Arlinghaus; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-04

Review 6.  Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Authors:  Claude Haan; Iris Behrmann; Serge Haan
Journal:  J Cell Mol Med       Date:  2010-01-28       Impact factor: 5.310

Review 7.  Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms.

Authors:  Lasse Kjær
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.